The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
Freeman et al.·International urogynecology journal and pelvic floor dysfunctionImpact 1.4
Klarer NutzenGRADEHoch207 Zitate
Stichproben = 630 Pat.
Dauerunklar
KontrollePlacebo
EndpunktInkontinenzepisoden
Verblindungdoppelblind
DesignRandomized Controlled Trial, Multicenter Study
Cannabinoidkombination
Applikationoral
”Kernaussage
Cannabis-Extrakt und THC zeigten signifikante Reduktionen von Harndrangs-Inkontinenz-Episoden im Vergleich zu Placebo (38% bzw. 33% vs. 18% Reduktion), mit p-Werten von 0,005 bzw. 0,039.
Zusammenfassung
Multizentrisches RCT (CAMS-LUTS, n=630 MS-Patienten): Cannabis-Extrakt reduzierte Dranginkontinenz-Episoden um 38 % (vs. 18 % Placebo, p=0,005); THC um 33 % (p=0,039). Beide Cannabinoide zeigten signifikante Überlegenheit gegenüber Placebo.
P
PopulationErwachsene mit Multipler Sklerose und Dranginkontinenz, n=630 (Substudie des CAMS-Trials)
I
InterventionOrales Cannabisextrakt oder Delta-9-THC (oral)
C
KontrollePlacebo (oral, matched)
O
OutcomeSignifikante Reduktion der Inkontinenzepisoden unter Cannabisextrakt (−38%, p=0,005) und THC (−33%, p=0,039) vs. Placebo (−18%)
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Hoch
Höchste von vier GRADE-Stufen, die Effektschätzung ist sehr verlässlich.
Design: Randomized Controlled Trial, Multicenter Study
Teilen
Abstract
To test whether cannabinoids reduce urge incontinence episodes without affecting voiding in patients with multiple sclerosis. This was part of the multicentre trial of the Cannabinoids in Multiple Sclerosis (CAMS) study. The CAMS study randomised 630 patients to receive oral administration of cannabis extract, Delta(9)-tetrahydrocannabinol (THC) or matched placebo. For this substudy subjects completed incontinence diaries. All three groups showed a significant reduction, p<0.01, in adjusted episode rate (i.e. correcting for baseline imbalance) from baseline to the end of treatment: cannabis extract, 38%; THC, 33%; and placebo, 18%. Both active treatments showed significant effects over placebo (cannabis extract, p=0.005; THC, p=0.039). The findings are suggestive of a clinical effect of cannabis on incontinence episodes in patients with MS. This is in contrast to the negative finding of the CAMS study, where no difference was seen in the primary outcome of spasticity.